Medical news
of the North Caucasus
Scientific journal
Mass media registration certificate dated December 7, 2006.
Series ПИ #ФС 77-26521.
Federal service for surveillance over non-violation of the legislation in the sphere of mass communications and protection of cultural heritage.
ISSN 2073-8137

Site search

Correspondence address
310 Mira Street, Stavropol, Russia, 355017

+7 865 2352511, +7 865 2353229.


Soluble molecules of immunoglobulins superfamily in rheumatoid arthritis

[Internal diseases]
Pavel Koroy; Vijaya Sarithala; Alexandr Yagoda;

Relationship of intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and platelet-endothelial cell adhesion molecule-1 (PECAM-1) blood levels with features of course of rheumatoid arthritis was studied. 134 patients with rheumatoid arthritis (104 women, 30 men) at age from 20 to 66 years included in study. Duration of joint syndrome was 11.06±0.72 years. In majority of patients high degree of activity, III radiological stage, II and III functional classes of rheumatoid arthritis were diagnosed. Plasma concentration of adhesion molecules was studied by means of ELISA.
Increase of levels of all adhesion molecules was observed (p<0.05). concentration of VCAM-1 and PECAM-1 in plasma was higher in seropositive patients or in presence of antibodies to cyclic citrullinated protein (p<0.05). In patients with late clinical stage levels of ICAM-1 and PECAM-1 were higher, than in early rheumatoid arthritis (р<0.05). High activity of disease was combined with raised plasma levels of ICAM-1 (р<0.05). Presense of systemic manifestations of disease and hematological disorders (hyperthrombocytosis) was accompanied by higher blood levels of all adhesion molecules (p<0.05). In values of SCORE scale of 5 and more points concentration of ICAM-1 and VCAM-1 in blood was higher (p<0.05), than in cases of low and moderated cardiovascular risk.
Thus, the pathogenetic importance of immunoglobulins superfamily molecules in formation and progressing of rheumatoid arthritis is proved. Strengthening of adhesive function of endothelium is interfaced to increased cardiovascular risk.


1. Gilyazova G. I., Mukhoramova I. S., Rudenko Yu. A., Koroy P. V. Role of adhesion molecules in immune response. Vestnik Molodogo Uchenogo. – Journal of Young Scientist. 2012;2:21–27.
2. Yemelyanchik E. Yu., Salmina A. B., Mikhailova A. K., Kirillova E. P., Pozhilenkova E. A. [et al.] Mechanisms of development of endothelial dysfunction in children with different activity of juvenile arthritis. Rossiyskiy Pediatricheskiy Zhurnal. – Russian Pediatric Journal. 2012;4:14–18 (in Russian).
3. Komarova E. B. Changes of endothelial regulation of vascular tonus and intercellular adhesion molecule depending of the severity of rheumatoid arthritis. Zabaykalskiy meditsinskiy vestnik. – Transbaikalian Medical Bulletin. 2015;2:43–46 (in Russian).
4. Komarova E. B., Rebrov B. A. Changes of IСAM-1 level in the blood of patients with rheumatoid arthritis. Ukrainskiy Revmatologichniy Zhurnal. – Ukrainian Rheumatologic Journal. 2011;3:79–81 (in Russian).
5. Balanescu S., Calmac L., Constantinescu D., Marinescu M., Onut R. [et al.] Systemic inflammation and early atheroma formation: are they related? Maedica. 2010;5:292-301.
6. Corona-Sanchez E. G., Gonzalez-Lopez L., Munoz-Valle J. F., Vazquez-Del Mercado M., Lopez-Olivo M. A. [et al.] Circulating E-selectin and tumor necrosis factoralpha in extraarticular involvement and joint disease activity in rheumatoid arthritis. Rheumatol. Int. 2009;29(3):281–286. doi: 10.1007/s00296-008-0688-3
7. Dessein P. H., Joffe B. I., Singh S. Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res. Ther. 2005;7(3):634–643. doi: 10.1186/ar1717
8. Elshabrawy H. A., Chen Z., Volin M. V., Ravella S., Virupannavar S. [et al.] The pathogenic role of angiogenesis in rheumatoid arthritis. Angiogenesis. 2015;18(4):433–448. doi: 10.1007/s10456-015-9477-2
9. Foster W., Shantsila E., Carruthers D., Lip G. Y., Blann A. D. Circulating endothelial cells and rheumatoid arthritis: relationship with plasma markers of endothelial damage/dysfunction. Rheumatology. 2009;48(3):285–288. doi: 10.1093/rheumatology/ken486
10. Gonzalez-Gay M. A., Gonzalez-Juanatey C. Inflammation, endothelial function and atherosclerosis in rheumatoid arthritis. Arthritis Res. Ther. 2012;14:122. doi: 10.1186/ar3891
11. Gonzales-Gay M. A., Garcia-Unzueta M. T., de Matias J. M., Gonzalez-Juanatey C., Garcia-Porrua C. [et al.] Influence of anti-TNF-a infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 2006;24(4):373–379.
12. Gorska A., Kowal-Bielecka O., Urban M., Chlabicz S., Sienkiewicz J. [et al.] Impairment of microcirculation in juvenile idiopathic arthritis – studies by nail-fold videocapillaroscopy and correlation with serum levels of sICAM and VEGF. Folia Hystochem. Cytobiol. 2008;46(4):443–447. doi: 10.2478/v10042-008-0062-z
13. Klimek E., Skalska A., Kwaśny-Krochin B., Surdacki A., Sulicka J. [et al.] Differential associations of inflammatory and endothelial biomarkers with disease activity in rheumatoid arthritis of short duration. Mediators Inflamm. 2014;2014:681635. doi: org/10.1155/2014/681635
14. Klimiuk P. A., Fiedorczyk M., Sierakowski S., Chwiecko J. Soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) in patients with early rheumatoid arthritis. Scand. J. Rheumatol. 2007;36(5):345–350. doi: 10.1080/03009740701406460
15. Naranjo A., Sokka T., Descalzo M. A., Calvo-Alén J., Hørslev-Petersen K. [et al.] Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST_RA study. Arthritis Res. Ther. 2008;10(2):30. doi: 10.1186/ar2383
16. Navarro-Hernøndez R. E., Oregon-Romero E., Vázquez- Del Mercado M., Rangel-Villalobos H., Palafox-Sánchez C. A. [et al.] Expression of ICAM1 and VCAM1 serum levels in rheumatoid arthritis clinical activity. Association with genetic polymorphisms. Dis. Markers. 2009;26(3):119–126. doi: 10.3233/DMA-2009-0621
17. Pieringer H., Pichler M. Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications. QJM. 2011;104(1):13-26. doi: 10.1093/qjmed/hcq203
18. Puttevils D., De Vusser P., Geusens P., Dens J. Increased cardiovascular risk in patients with rheumatoid arthritis. Act Cardiol. 2014;69(2):111–118. doi: 10.2143/AC.69.2.3017291
19. Rioja I., Hughes F. J., Sharp C. H., Warnock L. C., Montgomery D. S. [et al.] Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor. Arthritis Rheum. 2008;58(8):2257-2267. doi: 10.1002/art.23667
20. Shu Q., Amin M. A., Ruth J. H., Campbell P. L., Koch A. E. Suppression of endothelial cell activity by inhibition of TNF alpha. Arthritis Res. Ther. 2012;14(2):R88. doi: 10.1186/ar3812
21. Vestweber D. Adhesion and signaling molecules controlling the transmigration of leukocytes through endothelium. Immunol. Rev. 2007;218:178–196. doi: 10.1111/j.1600-065X.2007.00533.x

Keywords: rheumatoid arthritis, immunoglobulins superfamily molecules, activity, systemic manifestations, cardiovascular risk

Stavropol State Medical Academy
Pyatigorsk State Research Institute of Balneotherapeutics
Pyatigorsk State Pharmaceutical Academy